(SER) Serina Therapeutics, Inc. Business Model Canvas Research

Regulatory and clinical advisors help Serina Therapeutics, Inc. lock FDA-facing plans, pick trial endpoints, and keep nonclinical, CMC, and safety packages aligned for neuroscience and vaccine assets. This support matters because one weak filing can delay an IND, while a clean package can speed review and improve approval readiness.

• Aligns FDA strategy and endpoints
• Supports nonclinical, CMC, safety
• Raises approval readiness

Potential pharma and biotech licensees can co-develop or license Serina Therapeutics, Inc.'s POZ-based assets and delivery platform, turning R&D into non-dilutive value. For a cash-limited biotech model, these deals can add upfront payments, development support, and commercialization reach without heavy equity dilution.

• Co-develop POZ assets
• License delivery technology
• Bring capital and expertise
• Expand market access

Serina Therapeutics, Inc. uses regulatory strategy and CMC work to build IND-enabling packages, lock in quality docs, and keep manufacturing and release testing ready for FDA review. An IND has a 30-day FDA review clock, so tight CMC control helps prevent delays and keeps each program aligned with agency expectations.

• Build IND-ready quality files
• Support process and release testing
• Stay within FDA 30-day review timing

In FY2025, Serina Therapeutics used business development to seek licensing, collaboration, and funding deals that can turn POZ technology into non-dilutive cash and milestone income. That helps monetize the platform beyond internal drug assets and lowers dependence on a single lead candidate.

• License POZ for outside programs
• Use collaborations to share risk
• Seek funding to extend runway
• Spread value across more assets

Serina Therapeutics, Inc. relies on its intellectual property portfolio to protect its platform chemistry, formulations, and lead therapeutic uses, which is central to licensing leverage and future commercialization. For a preclinical company with no product revenue, IP is a core valuation driver because it can create exclusivity and strengthen partner talks.

• Protects platform chemistry and formulations
• Supports licensing exclusivity
• Raises partnering and valuation appeal

Serina Therapeutics, Inc.'s research and development capability is the core engine behind its lab work, data systems, and development workflows, letting teams test, analyze, and refine programs in fast loops. That capability is what moves assets from concept toward clinical milestones, where each decision can change cost, timing, and risk.

• Runs iterative testing
• Links lab data to decisions
• Pushes assets to clinical gates

Serina Therapeutics, Inc.'s platform versatility means one technology can support multiple therapeutic modalities, including neurology, pain, and vaccines, which widens the number of shots on goal without rebuilding the core platform each time. That kind of reuse can improve commercial optionality and lower R&D duplication across programs.

• One platform, multiple modalities
• Fits neurology, pain, vaccines
• Expands commercial optionality

Serina Therapeutics, Inc. has a modular asset base that can fit strategic partnerships and licensing deals, which makes it attractive to companies looking for differentiated delivery systems. That can create value before full product launch, since collaboration revenue, upfront payments, and milestone deals can arrive earlier than commercial sales.

• Modular assets support many deal types
• Delivery tech can stand out in partnering
• Value can emerge before launch

Serina Therapeutics, Inc. keeps a highly structured regulatory relationship through formal submissions and agency meetings, so the work is documentation-heavy and compliance-led. That kind of engagement can slow or reset study timelines, because each filing and feedback loop can change trial design, CMC plans, or review timing.

• Formal FDA-style submissions
• Meeting-driven, documented dialogue
• Compliance controls the pace
• Timeline risk rises with feedback

Serina Therapeutics, Inc. depends on clinical site investigators to recruit, dose, and monitor patients, so each trial site must get protocol training and steady support. This relationship is critical for enrollment speed and clean data, especially when the Company is still pre-revenue and execution quality drives every development milestone.

• Investigators drive recruitment
• Training reduces protocol errors
• Site support protects data quality
• Enrollment speed shapes trial risk

Serina Therapeutics, Inc.’s corporate website and investor materials are the main low-cost channel to publish pipeline updates, platform thesis, and SEC filings to investors, partners, and analysts. The site can centralize 10-K, 10-Q, and 8-K updates, so one page supports outreach across 3 core audiences.

• Pipeline status in one place
• Corporate updates and filings
• Supports investor and partner outreach

Direct business development outreach at Serina Therapeutics, Inc. targets pharma, biotech, and vaccine partners to negotiate licenses, co-development deals, and strategic alliances. It is a core source of deal flow and non-dilutive financing, which matters for a clinical-stage company that must fund development without constant equity dilution.

• Targets pharma, biotech, vaccine partners
• Drives alliances and license deals
• Supports non-dilutive funding

Serina Therapeutics, Inc. targets healthcare providers and patients as future end users of approved therapies, especially neurologists, pain specialists, and epilepsy care teams. This matters at scale: epilepsy affects about 50 million people worldwide, and these users want better dosing control and tighter symptom relief for hard-to-treat CNS conditions.

• Neurologists, pain specialists, and epilepsy teams
• Patients needing better dose control
• Symptom relief as the main value driver

Serina Therapeutics, Inc. relies on public and private funding sources such as investors, grant makers, and strategic partners. For a pre-commercial biotech, these groups fund R&D through equity, milestone payments, and research awards, helping cover long development cycles before product revenue starts.

• Investors fund equity raises

• Grant makers support research awards

• Partners add milestone capital

Regulatory and quality expenses cover FDA submissions, consultant support, audits, and compliance systems, and they are a core cost for Serina Therapeutics, Inc. because IND work and later approval steps depend on them. For a clinical-stage biotech, these spend lines help reduce trial delays, inspection risk, and rework across development.

• IND filings and amendment support

• Quality audits and SOP systems

• Compliance work lowers development risk

Serina Therapeutics, Inc.'s general and administrative costs cover personnel, legal, finance, facilities, and public-company overhead, so this line keeps corporate and partner-facing work running from Huntsville, Alabama. For a small public biotech, this is the fixed-cost base that supports SEC reporting, governance, and business development.

• Personnel and office overhead
• Legal and finance support
• Huntsville facilities costs
• Public-company reporting duties
• Partner-facing corporate work

As of FY2025, Serina Therapeutics has no approved products, so royalty income is $0 today. The upside is long-dated: if a licensed asset clears FDA or EMA approval and starts sales, royalties can turn into recurring cash, often tied to low-single-digit to mid-single-digit % of net sales.

• Only pays after approval and launch
• Creates long-term upside without direct sales cost

Government or grant support can give Serina Therapeutics, Inc. non-dilutive cash for research and translational work, which fits platform science and infectious disease programs. For an early-stage biotech, this funding can extend runway without adding equity dilution and can help de-risk preclinical work before larger partner or investor capital.

• Non-dilutive research funding
• Supports early-stage innovation
• Useful in infectious disease work